Jefferies Reiterates a 'Buy' on WuXi PharmaTech (WX); Demand As Good As Ever

Jefferies reiterates a 'Buy' on WuXi PharmaTech (NYSE: WX) price target of $17.00.

Analyst, David Windley, said, "WX's strong finish to 2011 and impressive 2012 revenue growth guidance of 15-20% are encouraging signs. Recent strategic moves by management should position WX to maintain industry-leading topline growth, though the investments would drag on '12 margins. Double-digit EPS growth in 2013+ should warrant a higher P/E...WX is the cheapest CRO in our universe."

For an analyst ratings summary and ratings history on WuXi PharmaTech click here. For more ratings news on WuXi PharmaTech click here.

Shares of WuXi PharmaTech closed at $13.88 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Benchmark Reiterates Buy Rating on Rank One Computing (ROC)
• Viking Holdings (VIK) PT Raised to $82 at Mizuho